Drug intelligence / Profile preview

lidocaine + epinephrine + gadoterate meglumine

Development stage
Unknown
Lead developer
Guerbet
Modality
Small Molecules
Administration
Local Injection, Infiltration, Intra-articular Injection, Intralesional Injection, Soft Tissue Injection
01

Overview

This is a combination drug product containing three active ingredients: - **Lidocaine** is a local anesthetic that works by blocking sodium channels in neuronal cell membranes, thereby inhibiting nerve impulse conduction and providing local numbness or anesthesia. - **Epinephrine** (also known as adrenaline) is a sympathomimetic agent that acts primarily on alpha and beta adrenergic receptors. When combined with lidocaine, it causes vasoconstriction at the site of injection, which reduces bleeding and prolongs the duration of anesthesia by slowing systemic absorption of lidocaine. - **Gadoterate meglumine** is a gadolinium-based contrast agent used to enhance visualization during magnetic resonance imaging (MRI). It works by altering the magnetic properties of nearby water molecules, increasing contrast between tissues for improved imaging[1][2][3][5][6]. This specific combination may be used in specialized interventional radiology or MRI-guided procedures where both local anesthesia and enhanced imaging are required. However, this exact triple combination does not appear to be marketed under any unique brand name; it represents an admixture prepared for procedural use.

02

Targets

ADRB1 (β1)NaV alpha (Voltage-gated sodium channel alpha subunit family)ADRA1A (α1A)

Beyond the preview

Go deeper on lidocaine + epinephrine + gadoterate meglumine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + epinephrine + gadoterate meglumine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call